|
Could histologic healing be a new treatment target in patients with ulcerative colitis?
Soyoung Kim, Sang Hyoung Park
Korean J Intern Med. 2024;39(1):2-3. Published online January 1, 2024
|
|
|
Gastroenterology
Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park; on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases (KASID)
Korean J Intern Med. 2023;38(5):661-671. Published online July 26, 2023
Background/Aims: The short- and long-term effects of adalimumab (ADA) on Korean patients with intestinal Behcet’s disease (BD) for remain unclear. Therefore, a multicenter study was performed to evaluate the efficacy and safety of ADA in Korean patients with intestinal BD in a real-world setting.
..
|
|
|
Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
Korean J Intern Med. 2022;37(6):1140-1152. Published online June 22, 2022
Background/Aims: We aimed to investigate the oral beclomethasone dipropionate’s (BDP) efficacy as an add-on therapy and to clarify the predictive factor for response to oral BDP in Korean ulcerative colitis (UC) patients.
Methods: Patients with a stable concomitant drug regimen with exposure to or..
|
|
|
Is radiological healing alone enough? ‘Can’t take my eyes off’ the mucosa
Su Hyun Park, Sang Hyoung Park
Korean J Intern Med. 2022;37(3):551-552. Published online April 28, 2022
|
|
|
Gastroenterology
Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases
Hee Seung Hong, Jiwon Jung, Sang Hyoung Park, Hwa Jung Kim, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Korean J Intern Med. 2022;37(1):73-84. Published online September 6, 2021
Background/Aims: Data on the immunoprotective status against measles, mumps, rubella, varicella zoster virus (VZV), hepatitis A virus (HAV), and Epstein-Barr virus (EBV) infection in patients with inflammatory bowel disease (IBD) are still lacking. Therefore, we investigated the seropositivity rates..
|
|
|
Development, validation, and application of a novel tool to measure disease-related knowledge in patients with inflammatory bowel disease
Hyuk Yoon, Suk-Kyun Yang, Hoonsub So, Ko Eun Lee, Sang Hyoung Park, Sung-Ae Jung, Joong Haeng Choh, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
Korean J Intern Med. 2019;34(1):81-89. Published online November 29, 2017
Background/Aims: The Crohn’s and Colitis Knowledge (CCKNOW) score does not reflect updated knowledge relating to inflammatory bowel disease (IBD). The aim of this study was to develop, validate, and apply a novel tool to measure disease-related knowledge in IBD patients.
Methods: A questionnaire ..
|
|
|
Rheumatology
Ileocolonoscopic findings in patients with ankylosing spondylitis: a single center retrospective
study
Soo Min Ahn, Yong-Gil Kim, Seung-Hyeon Bae, Doo-Ho Lim, Seokchan Hong, Sang Hyoung Park, Chang-Keun Lee, Bin Yoo
Korean J Intern Med. 2017;32(5):916-922. Published online August 11, 2017
Background/Aims: In some Western countries, up to 50% of patients with ankylosing spondylitis (AS) have subclinical gut inflammation. This study was conducted to evaluate the prevalence and severity of gut inflammation and to determine clinical factors associated with colonic inflammation in Korean ..
|
|
|
ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
Sang Hyoung Park, Shin Kim, Ok Bae Ko, Ja Eun Koo, Danbi Lee, Yong Pil Jeong, Jooryung Huh, Sung-Bae Kim, Sang We Kim, Jae-Lyun Lee, Cheolwon Suh
Korean J Intern Med. 2006;21(3):159-164. Published online September 30, 2006
BackgroundThe ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to..
|
|
|
